Skip to content
Procainamide
Procan, Procanbid, Procapan, Pronestyl, Pronestyl-sr (procainamide) is a small molecule pharmaceutical. Procainamide was first approved as Pronestyl on 1982-01-01. It is used to treat atrial fibrillation, atrial flutter, cardiac arrhythmias, supraventricular tachycardia, and ventricular premature complexes amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Procainamide hydrochloride
Tradename
Company
Number
Date
Products
PRONESTYLBristol Myers SquibbN-007335 DISCN1982-01-01
5 products, RLD
PRONESTYLBristol Myers SquibbN-017371 DISCN1982-01-01
3 products
PROCANBIDKing PharmaceuticalsN-020545 DISCN1996-01-31
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
procainamide hciANDA2023-04-24
procainamide hciANDA2023-04-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282—
cardiac arrhythmiasEFO_0004269D001145I49.9
supraventricular tachycardiaHP_0004755D013617I47.1
ventricular premature complexes—D018879I49.3
ventricular tachycardia—D017180I47.2
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BA: Antiarrhythmics, class ia
— C01BA02: Procainamide
HCPCS
Code
Description
J2690
Injection, procainamide hcl, up to 1 gm
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1——2—3
Type 2 diabetes mellitusD003924EFO_0001360E11———112
Intracranial hemorrhagesD020300EFO_0000551I62———2—2
Brain ischemiaD002545I67.82———2—2
Diabetic nephropathiesD003928EFO_0000401—1—1—2
HyperlipidemiasD006949EFO_0003774E78.5——11—2
GlomerulonephritisD005921N05———1—1
Iga glomerulonephritisD005922EFO_0004194———1—1
Coronary diseaseD003327———1—1
HypercholesterolemiaD006937HP_0003124———1—1
Show 5 more
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Peripheral arterial diseaseD058729EFO_0004265—1———1
Alzheimer diseaseD000544EFO_0000249F0311———1
DementiaD003704F0311———1
Cognitive dysfunctionD060825G31.8411———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePROCAINAMIDE
INNprocainamide
Description
Procainamide is a benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. It has a role as a sodium channel blocker, an anti-arrhythmia drug and a platelet aggregation inhibitor.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCN(CC)CCNC(=O)c1ccc(N)cc1
Identifiers
PDB—
CAS-ID51-06-9
RxCUI8700
ChEMBL IDCHEMBL640
ChEBI ID8428
PubChem CID4913
DrugBankDB01035
UNII IDL39WTC366D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,136 documents
View more details
Safety
Black-box Warning
Black-box warning for: Procainamide hci, Procainamide hci
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
177 adverse events reported
View more details